EcoDrugPlus

Calcium Voltage-Gated Channel Auxiliary Subunit Gamma 2

Ensembl ID : ENSSPAG00000005196
Gene Symbol: CACNG2
3 Cross references
200 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Gamma 2

Ensembl ID : ENSSPAG00000005997
Gene Symbol: CACNG2
3 Cross references
205 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Gamma 3

Ensembl ID : ENSSPAG00000013277
Gene Symbol: CACNG3
3 Cross references
178 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Gamma 4

Ensembl ID : ENSSPAG00000012827
Gene Symbol: CACNG4
3 Cross references
187 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Gamma 5

Ensembl ID : ENSSPAG00000017947
Gene Symbol: CACNG5
3 Cross references
169 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Gamma 6

Ensembl ID : ENSSPAG00000022510
Gene Symbol: CACNG6
3 Cross references
176 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Gamma 7

Ensembl ID : ENSSPAG00000015810
Gene Symbol: CACNG7
3 Cross references
187 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Gamma 8

Ensembl ID : ENSSPAG00000022507
Gene Symbol: CACNG8
1 Cross references
159 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 D

Ensembl ID : ENSSPAG00000006259
Gene Symbol: CACNA1D
4 Cross references
208 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 E

Ensembl ID : ENSSPAG00000011263
Gene Symbol: CACNA1E
3 Cross references
214 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 E

Ensembl ID : ENSSPAG00000015490
Gene Symbol: CACNA1E
3 Cross references
208 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 G

Ensembl ID : ENSSPAG00000023276
Gene Symbol: CACNA1G
3 Cross references
196 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).